Concepedia

Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

Avia D. Wilkerson, Prerana Bangalore Parthasarathy, Nickolas Stabellini, Carley Mitchell, Paul G. Pavicic, Pingfu Fu, Amit Rupani, Hana Husic, Patricia Rayman, Shadi Swaidani,

Clinical Cancer Research · 2023 · 11 citations · 35 references

DOIFull text

Open access

Abstract

Pretreatment tissue sampling in mTNBC treated with CNP reveals transcriptomic signatures that may predict radiographic responses to chemo-immunotherapy.

References

35

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.4K citations

, , +14

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.1K citations · Full text

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Aleix Prat, Joel S. Parker, Olga Karginova et al. · Breast Cancer Research · 2010 · 2.1K citations · Full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

, , +7